Millions of people are affected by AD, taking a significant emotional and financial toll on these individuals and their families. Currently, there are no treatments for AD or definitive predictors of its onset. Team BRAIN is looking to correlate biomarker levels and lifestyle choices with the progression of Alzheimer’s Disease. Each participant’s physical health and cognitive function will be assessed using an Alzheimer’s Cognitive Battery. Enzyme-linked immunosorbent assays will be used to analyze the levels of biomarkers and observe their change in concentration over a six month period, which will be compared with data from the self report survey and cognitive battery results. We expect to find that the blood biomarkers we test will become more prominent after the six month period. By analyzing changes in a set of biomarkers characteristic of the progression of Alzheimer’s Disease, we hope to propose a novel, quantitative way to diagnose the disease while paving a way to identify potential drug targets in the future.